Mitsushige Sugimoto
Center for Clinical Research
Hamamatsu University School of Medicine
1-20-1 Handayama
Higashi-ku
Japan
Name/email consistency: high
- Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. Sugimoto, M., Yamaoka, Y., Furuta, T. World J. Gastroenterol. (2010)
- Role of angiotensinogen gene polymorphism on Helicobacter pylori infection-related gastric cancer risk in Japanese. Sugimoto, M., Furuta, T., Shirai, N., Kodaira, C., Nishino, M., Ikuma, M., Sugimura, H., Hishida, A. Carcinogenesis (2007)
- Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Sugimoto, M., Furuta, T., Shirai, N., Kodaira, C., Nishino, M., Ikuma, M., Ishizaki, T., Hishida, A. Helicobacter (2007)
- Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. Sugimoto, M., Furuta, T., Shirai, N., Nakamura, A., Kajimura, M., Sugimura, H., Hishida, A. J. Gastroenterol. Hepatol. (2007)
- Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Sugimoto, M., Furuta, T., Shirai, N., Kodaira, C., Nishino, M., Yamade, M., Ikuma, M., Watanabe, H., Ohashi, K., Hishida, A., Ishizaki, T. Expert. Opin. Pharmacother (2007)
- Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. Sugimoto, M., Furuta, T., Shirai, N., Nakamura, A., Xiao, F., Kajimura, M., Sugimura, H., Hishida, A. J. Gastroenterol. Hepatol. (2007)
- Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Sugimoto, M., Furuta, T., Shirai, N., Ikuma, M., Hishida, A., Ishizaki, T. Clin. Pharmacol. Ther. (2006)
- Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Sugimoto, M., Furuta, T., Shirai, N., Ikuma, M., Sugimura, H., Hishida, A. Cancer Epidemiol. Biomarkers Prev. (2006)
- Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Sugimoto, M., Furuta, T., Shirai, N., Ikuma, M., Hishida, A., Ishizaki, T. Clin. Pharmacol. Ther. (2006)
- Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Sugimoto, M., Furuta, T., Shirai, N., Nakamura, A., Kajimura, M., Hishida, A., Ohashi, K., Ishizaki, T. Clin. Pharmacol. Ther. (2005)
- Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Sugimoto, M., Furuta, T., Shirai, N., Nakamura, A., Kajimura, M., Sugimura, H., Hishida, A., Ishizaki, T. Aliment. Pharmacol. Ther. (2005)
- Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Sugimoto, M., Furuta, T., Shirai, N., Kajimura, M., Hishida, A., Sakurai, M., Ohashi, K., Ishizaki, T. Clin. Pharmacol. Ther. (2004)